COVID-19 Care

Infusion Associates offers one IV medication and two active research studies to aid in the treatment of COVID-19. There is no cost to become involved in our research studies (and you are compensated for your involvement), and there are options for both low-risk healthy individuals as well as higher risk immunocompromised individuals. **These treatment opportunities are currently only available for patients in the greater Grand Rapids, MI area.

About COVID-19 

According to the CDC, COVID-19 is a respiratory disease caused by SARS-CoV-2, a new coronavirus discovered in 2019. The virus is thought to spread mainly from person to person through respiratory droplets produced when an infected person coughs, sneezes, or talks. Some people who are infected may not have symptoms. For people who have symptoms, illness can range from mild to severe. Adults 65 years and older and people of any age with underlying medical conditions are at higher risk for severe illness. People 6 months of age and older should get COVID-19 vaccines to prevent getting and spreading the illness.

Infusion Treatment

We are only able to administer this medication at our Grand Rapids, MI location. Please speak with your healthcare provider for more information if you think this therapy might be right for you.

VEKLURY® is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) who are:

• Hospitalized, or
• Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

For more information, please refer to the VEKLURY® website and/or prescribing information. 

Clinical Research Studies

Shionogi Study for COVID-19 (Oral Medication)

This study, called the ACTIV-2d (SCORPIO-HR) study, is a global Phase 3 multicenter study evaluating the safety and efficacy of the COVID-19-antiviral agent S-217622 to reduce the duration of COVID-19 symptoms. The study drug is a 3CL protease inhibitor as a once-daily oral treatment for low-risk, non-hospitalized adults with COVID-19 within five days of symptom onset.

You may be able to join the study if you:

  • Are 18 or older
  • Have low risk of progression to severe COVID-19
  • Have tested positive for COVID-19 within the past 5 days
  • Have had symptoms for 5 days or less
  • Are not currently hospitalized
  • Are able to travel to the study site in Grand Rapids, MI

If you join this study, you will be compensated $100 per visit (6 in-person visits required), have access to travel reimbursement and/or coordination, and receive either oral study drug or placebo. The study lasts 24 weeks and participating patients will be asked to record symptoms for 29 days in an electronic diary.

NIH Study for COVID-19 (IV Medication)

The study team hopes to find out if giving anti-SARS-CoV-2 hyperimmunoglobulin (hIVIG) to people early in their infection with COVID-19, before the body has had a chance to make its own antibodies, can help prevent bad effects from COVID-19 and enable them to stay out of the hospital.

You may be able to join the study if you:

  • Are 55 or older, OR are 18 or older with a weakened immune system
  • Have tested positive for COVID-19 within the past 5 days
  • Are not having symptoms, OR have had symptoms for 5 days or less
  • Are not currently hospitalized

If you join this study, you will be compensated for your time and travel, and receive either study drug (hIVIG) or placebo given through a vein in the arm as a single dose. You will also get the usual treatment and care for COVID-19 according to local guidelines. The study lasts 28 days with some of the scheduled study visits taking place over the phone.

Frequently Asked Questions

We see positive COVID-19 patients in a suite separate of our Grand Rapids, MI infusion clinic:

3230 Eagle Park Dr. NE, Suite 200
Grand Rapids, MI 49525

  1. Ask your healthcare provider to fax us a completed order form for your medication, clinical notes, demographics and your insurance card to (616) 818-4484.
  2. Providers can find order forms on our medications page.
  3. We will then verify benefits, obtain any required prior authorizations, and contact you to schedule an appointment.
  1. Print and fill out the referral form.
  2. Fax the referral form, a copy of the patient’s positive COVID-19 test results, demographics, current medication list and recent visits notes to (616) 818-4484.
  3. We will contact them to screen for eligibility and keep you informed every step of the way.